PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL.
E
E
Schachter-Tokarz
C
C
Kelaidi
B
B
Cassinat
C
C
Chomienne
C
C
Gardin
E
E
Raffoux
H
H
Dombret
P
P
Fenaux
R
R
Gallagher
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D017434:Protein Structure, Tertiary; D017384:Sequence Deletion / Q000235:genetics*; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin